A Phase 2a Randomized, Double-Blind, Dose-Optimizing Study to Evaluate the Immunogenicity and Safety of a Bivalent DNA Vaccine for Hemorrhagic Fever with Renal Syndrome Delivered by Intramuscular Electroporation
| Autor: | B Hill, Connie S. Schmaljohn, Melanie V. Cohen, Brandon Somerville, M Wisniewski, Mariano Sanchez-Lockhart, K Mills, Kristopher M. Paolino, Drew Hannaman, Jay W. Hooper, Matthew D. Josleyn, Steven A. Kwilas, Shane A. Norris |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
DNA vaccine electroporation 030106 microbiology Immunology lcsh:Medicine Neutralization Article hantavirus DNA vaccination 03 medical and health sciences Plaque reduction neutralization test Pseudovirion Drug Discovery hemorrhagic fever with renal syndrome Medicine Pharmacology (medical) Pharmacology biology business.industry Immunogenicity lcsh:R biology.organism_classification Virology Vaccination Titer 030104 developmental biology Infectious Diseases Puumala virus business |
| Zdroj: | Vaccines, Vol 8, Iss 377, p 377 (2020) Vaccines Volume 8 Issue 3 |
| Popis: | Hantaan virus (HTNV) and Puumala virus (PUUV) are pathogenic hantaviruses found in Asia and Europe, respectively. DNA vaccines targeting the envelope glycoproteins of these viruses have been constructed and found to elicit neutralizing antibodies when delivered to humans by various technologies including intramuscular electroporation. Here, we report findings from a Phase 2a clinical trial of a combined HTNV/PUUV DNA vaccine delivered at varying doses and administration schedules using the Ichor Medical Systems TriGrid intramuscular electroporation delivery technology. The study was designed to characterize the effects of DNA vaccine dose and number of administrations on the frequency and magnitude of immunological response. Subjects (n = 120) were divided into four cohorts. Cohorts 1 and 2 received a dose of 2 mg of DNA (1 mg per plasmid), and cohorts 3 and 4 received a dose of 1 mg of DNA (0.5 mg per plasmid) each vaccination. Each of the four cohorts received a series of four administrations (days 0, 28, 56 and 168). For cohorts 1 and 3, the DNA vaccine candidate was delivered at each of the four administrations. For cohorts 2 and 4, in order to maintain blinding, subjects received the DNA vaccine on days 0, 56 and 168, but on day 28 received only the phosphate buffered saline vehicle rather the DNA vaccine. Sera were collected on days 0, 28, 56, 84, 140, 168, 196, 252 and 365 and evaluated for the presence of neutralizing antibodies by PUUV and HTNV pseudovirion neutralization assays (PsVNAs). Day 84 was also evaluated by a plaque reduction neutralization test (PRNT). Overall the PsVNA50 geometric mean titers (GMTs) and seropositivity rates among cohorts were similar. Cohort 3 exhibited the highest frequency of subjects that became seropositive to both PUUV and HTNV after vaccination, the highest peak GMT against both viruses, and the highest median titers against both viruses. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|